Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: A review

Therapeutic Advances in Hematology

Volumn 5, Issue 5, 2014, Pages 139-152

  Mewawalla, Prerna ^a   Nathan, Sunita ^b  

^a WESTERN PENNSYLVANIA HOSPITAL   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

chimeric antigen receptor T cells; chronic lymphocytic leukemia; immunomodulatory drugs; targeted agents; transplant

Indexed keywords

EID: 84993748430     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620714550773     Document Type: Review

References (86)

1. American Cancer Society (2013) Cancer Facts & Figures – 2013. Atlanta, GA: American Cancer Society.
2. Adams J. Cory S. (2007) The BCL-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324–1337.
3. Badoux X. Keating M. Wen S. Wierda W. O'Brien S. Faderl S. et al. (2013) Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 31: 584–591.
4. Binet J. Auquier A. Dighiero G. Chastang C. Piguet H. Goasguen J. et al. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198–206.
5. Brown J. (2013) Targeted therapy for CLL: focusing on the B cell receptor (BCR) pathway. Presented at 11th International Congress on Targeted Therapies, 16–17 August 2013, Washington, DC.
6. Brown J. Kim H. Armand P. Cutler C. Fisher D. Ho V. et al. (2012) Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 27: 362–369.
7. Burger J. Ghia P. Rosenwald A. Caligaris-Cappio F. (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114: 3367–3375.
8. Burger J. Keating M. Wierda W. Hoellenriegel J. Ferrajoli A. Faderl S. et al. (2012) The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. Blood (ASH Annual Meeting Abstracts) 120: abstract 187.
9. Byrd J. Brown J. O'Brien S. Barrientos J. Kay N. Reddy N. et al. (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371: 213-223.
10. Byrd J. Furman R. Coutre S. Flinn I. Burger J. Blum K. et al. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369: 32–42.
11. Castro J. Sandoval-Sus J. Bole J. Rassenti L. Kipps T. (2008) Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 22: 2048–2053.
12. Chanan-Khan A. Miller K. Musial L. Lawrence D. Padmanabhan S. Takeshita K. et al. (2006) Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24: 5343–5349.
13. Chevallier P. Penther D. Avet-Loiseau H. Robillard N. Ifrah N. Mahe B. et al. (2002) CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 116: 142–150.
14. Coiffier B. Lepretre S. Pedersen L. Gadeberg O. Fredriksen H. van Oers M. et al. (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood 111: 1094–1100.
15. Costa S. Afrin L. Bentz T. Salzer S. (2012) Phase 2 trial of intracycle sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 120: abstract 3933.
16. Crespo M. Bosch F. Villamor N. Bellosillo B. Colomer D. Rozman M. et al. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348: 1764–1775.
17. Cuneo A. Cavazzini F. Ciccone M. Daghia G. Sofritti O. Saccenti E. et al. (2014) Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. Cancer Med 3: 555–564.
18. Döhner H. Stilgenbauer S. Benner A. Leupolt E. Kröber A. Bullinger L. et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910–1916.
19. Dreger P. (2013) The evolving role of stem cell transplantation in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 27: 355–369.
20. Dreger P. Brand R. Milligan D. Corradini P. Finke J. Deliliers G. et al. (2005) Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19: 1029–1033.
21. Dreger P. Corradini P. Kimby E. Michallet M. Milligan D. Schetelig J. et al. (2006) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21: 12–17.
22. Dreger P. Döhner H. Ritgen M. Böttcher S. Busch R. Dietrich S. et al. (2010) Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3Z Trial. Blood 116: 2438–2447.
23. Dreger P. Stilgenbauer S. Boettcher S. Ritgen M. Dietrich S. Bunjes D. et al. (2008) Prognostic factors for outcome of nonmyeloablative allogeneic stem cell transplantation (NST) in poor-risk chronic lymphocytic leukemia (CLL): final results from a prospective multicenter trial (GCLLSG CLL3X study). Blood (ASH Annual Meeting Abstracts) 112: abstract 565.
24. Dungarwalla M. Evans S. Riley U. Catovsky D. Dearden C. Matutes E. (2008) High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 93: 475–476.
25. Farina L. Carniti C. Dodero A. Vendramin A. Raganato A. Spina F. et al. (2009) Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 94: 654–662.
26. FDA (2014) Drug safety and availability. FDA statement: FDA halts clinical trial of drug revlimid (lenalidomide) for chronic lymphocytic leukemia due to safety concerns. US Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm361444.htm
27. Flinn I. Harwin W. Ward P. Doss H. Papish S. Hainsworth J. et al. (2012) Phase II trial of ofatumumab (OFA) for older patients and patients who refuse fludarabine-based regimens with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood (ASH Annual Meeting Abstracts) 120.
28. Foon K. Boyiadzis M. Land S. Marks S. Raptis A. Pietragallo L. et al. (2009) Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27: 498–503.
29. Furman R. Sharman J. Coutre S. Cheson B. Pagel J. Hillmen P. et al. (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370: 997–1007.
30. Goede V. Fischer K. Busch R. Engelke A. Eichhorst B. Wendtner C. et al. (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370: 1101–1110.
31. Gribben J. Zahrieh D. Stephans K. Bartlett-Pandite L. Alyea E. Fisher D. et al. (2005) Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106: 4389–4396.
32. Hallek M. Fischer K. Fingerle-Rowson G. Fink A. Busch R. Mayer J. et al. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. The Lancet 376: 1164–1174.
33. Hamblin T. Orchard J. Ibbotson R. Davis Z. Thomas P. Stevenson F. et al. (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99: 1023–1029.
34. Herman S. Gordon A. Hertlein E. Ramanunni A. Zhang X. Jaglowski S. et al. (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117: 6287–6296.
35. Herter S. Herting F. Mundigl O. Waldhauer I. Weinzierl T. Fauti T. et al. (2013) Preclinical activity of the type II CD20 antibody GA 101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 12: 2031–2042.
36. Herth I. Dietrich S. Benner A. Hegenbart U. Rieger M. Stadtherr P. et al. (2014) The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. Ann Oncol 25: 200–206.
37. Hillmen P. Robak T. Janssens A. Govindbabu K. Grosicki S. Mayer J. et al. (2013) Ofatumumab+ chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911). Blood 122: 528–538.
38. Hillmen P. Skotnicki A. Robak T. Jaksic B. Dmoszynska A. Wu J. et al. (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25: 5616–5623.
39. Ibrahim S. Keating M. Do K. O'Brien S. Huh Y. Jilani I. et al. (2001) CD38 expression as an important prognostic factor in B-cell chronic lmphocytic leukemia. Blood 98: 181–186.
40. Jeromin S. Weissmann S. Haferlach C. Dicker F. Bayer K. Grossmann V. et al. (2013) SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO 1 AND TP 53 in 1160 untreated CLL patients. Leukemia 28: 108–117.
41. Jones J. Byrd J. (2014) How will B-cell-receptor-targeted therapies change future CLL therapy? Blood 123: 1455–1460.
42. Kalos M. Frey N. Grupp S. Loren A. Jemison C. Gilmore J. et al. (2013) Chimeric antigen receptor modified T cells directed against CD19 (CTL019 cells) have long-term persistence and induce durable responses in relapsed, refractory CLL. Blood 122: 4162–4163.
43. Keating M. Flinn I. Jain V. Binet J. Hillmen P. Byrd J. et al. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99: 3554–3561.
44. Keating M.J. O'Brien S. Albitar M. Lerner S. Plunkett W. Giles F. et al. (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23: 4079–4088.
45. Kharfan-Dabaja M. Bazarbachi A. (2012) Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens. Cancer Control 19: 68-75.
46. Kharfan-Dabaja M. Chavez J. Khorfan K. Pinilla-Ibarz J. (2008) Clinical and therapeutic implications of the mutational status of IGVH in patients with chronic lymphocytic leukemia. Cancer 113: 897–906.
47. Kharfan-Dabaja M. Pidala J. Kumar A. Terasawa T. Djulbegovic B. (2012) Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplant 47: 1164–1170.
48. Khouri I. Bassett R. Poindexter N. O'Brien S. Bueso-Ramos C. Hsu Y. et al. (2011) Nonmyeloablative allogeneic stem cell transplantation in relapsed / refractory chronic lymphocytic leukemia. Cancer 117: 4679–4688.
49. Khouri I. Saliba R. Admirand J. O'Brien S. Lee M. Korbling M. et al. (2007) Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137: 355–363.
50. Kochenderfer J. Dudley M. Feldman S. Wilson W. Spaner D. Maric I. et al. (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709–2720.
51. Koehler P. Schmidt P. Hombach A. Hallek M. Abken H. (2012) Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol 2012: 595060.
52. Lannutti B. Meadows S. Herman S. Kashishian A. Steiner B. Johnson A. et al. (2011) Cal-101, a P110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117: 591–594.
53. Michallet M. Archimbaud E. Bandini G. Rowlings P. Deeg H. Gahrton G. et al. (1996) HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 124: 311–315.
54. Molica S. Alberti A. (1987) Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 60: 2712–2716.
55. Montserrat E. Sanchez-Bisono J. Viñolas N. Rozman C. (1986) Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 62: 567–575.
56. Moreno C. Villamor N. Colomer D. Esteve J. Martino R. Nomdedéu J. et al. (2005) Allogeneic Stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23: 3433–3438.
57. National Comprehensive Cancer Network (2014) NCCN Clinical Practice Guidelines in Oncology. (NCCN Guidelines). Non-Hodgkin's Lymphomas. Fort Washington, PA: NCCN. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf
58. O'Brien S. Furman R. Coutre S. Sharman J. Burger J. Blum K. et al. (2014) Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1B/2 trial. Lancet Oncol 15: 48–58.
59. O'Brien S. Lamanna N. Kipps T. Flinn I. Zelenetz A. Burger (2013) A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K {delta}) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (Pts)> = 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ASCO Meeting Abstracts 31.
60. Oscier D. Rose-Zerilli M. Winkelmann N. de Castro D. Gomez B. Forster J. et al. (2013) The clinical significance of NOTCH 1 and SF3B1 mutations in the UK LRF CLL 4 trial. Blood 121: 468–475.
61. Pavletic S. Khouri I. Haagenson M. King R. Bierman P. Bishop M. et al. (2005) Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant Research. J Clin Oncol 23: 5788–5794.
62. Rai K. (2008) The natural history of CLL and new prognostic markers. Clin Adv Hematol Oncol 6: 4–5.
63. Rassenti L. Jain S. Keating M. Wierda W. Grever M. Byrd J. et al. (2008) Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112: 1923–1930.
64. Reddy N. Hernandez-Ilizaliturri F. Deeb G. Roth M. Vaughn M. Knight J. et al. (2008) Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 140: 36–45.
65. Rosenquist R. Cortese D. Bhoi S. Mansouri L. Gunnarsson R. (2013) Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? Leukemia Lymphoma 54: 2351–2364.
66. Rossi D. Gaidano G. (2012) Molecular genetics of high-risk chronic lymphocytic leukemia. Exp Rev Hematol 5: 593–602.
67. Schetelig J. Thiede C. Bornhäuser M. Schwerdtfeger R. Kiehl M. Beyer J. et al. (2003) Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 21: 2747–2753.
68. Schetelig J. van Biezen A. Brand R. Caballero D. Martino R. Itala M. et al. (2008) Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European group for blood and marrow transplantation analysis. J Clin Oncol 26: 5094–5100.
69. Schnaiter A. Paschka P. Rossi M. Zenz T. Bühler A. Winkler D. et al. (2013) NOTCH1, SF3B1, and TP 53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 122: 1266–1270.
70. Seymour et al. (2013) Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed / refractory (R/R) chronic lymphocytic leukemia (CLL). J Clin Oncol 31: (suppl; abstr 7018).
71. Siegel R. Naishadham D. Jemal A. (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11–30.
72. Smith A. Howell D. Patmore R. Jack A. Roman E. (2011) Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 105: 1684–1692.
73. Sorror M. Storer B. Maloney D. Sandmaier B. Martin P. Storb R. (2008) Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111: 446–452.
74. Sorror M. Storer B. Sandmaier B. Maris M. Shizuru J. Maziarz R. et al. (2008) Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 26: 4912–4920.
75. Souers A. Leverson J. Boghaert E. Ackler S. Catron N. Chen J. et al. (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19: 202–208.
76. Stephens D. Ruppert A. Jones J. Woyach J. Maddocks K. Jaglowski S. et al. (2014) Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del (17p13.1) karyotype at a single center. Leukemia 28: 1365-1368.
77. Stilgenbauer S. Cymbalista F. Leblond V. Delmer A. Mack S. Buehler A. et al. (2012) Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: updated results from a phase II study of the GCLLSG and FCGCLL/MW. Blood (ASH Annual Meeting Abstracts) 120.
78. Strati P. Keating M. O'Brien S. Ferrajoli A. Burger J. Faderl S. et al. (2014) Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99: 1350-1355.
79. Tam C. O'Brien S. Wierda W. Kantarjian H. Wen S. Do K. et al. (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112: 975–980.
80. Teeling J. French R. Cragg M. van Den Brakel J. Pluyter M. Huang H. et al. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793–1800.
81. Toze C. Galal A. Barnett M. Shepherd J. Conneally E. Hogge D. et al. (2005) Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant 36: 825–830.
82. Wierda W. Kipps T. Mayer J. Stilgenbauer S. Williams C. Hellmann A. et al. (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28: 1749–1755.
83. Wierda W. O'Brien S. Wang X. Faderl S. Ferrajoli A. Do K. et al. (2009) Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 27: 1637–1643.
84. Wierda W. Padmanabhan S. Chan G. Gupta I. Lisby S. Österborg A. (2011) Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 118: 5126–5129.
85. Woyach J. Ruppert A. Heerema N. Peterson B. Gribben J. Morrison V. et al. (2011) Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 29: 1349–1355.
86. Zenz T. Dreger P. Dietrich S. Boettcher S. Ritgen M. Winkler D. et al. (2010) Allogeneic stem cell transplantation can overcome the adverse prognostic impact of TP 53 mutation in chronic lymphocytic leukemia (CLL): results from the GCLLSG CLL3Z trial. Blood (ASH Annual Meeting Abstracts) 116.